Telbolife Beta 25 Tablet is a dual-action antihypertensive medication formulated to provide effective blood pressure control and cardiovascular protection in patients with moderate to severe hypertension. This fixed-dose combination includes Telmisartan, an angiotensin II receptor blocker (ARB), and Metoprolol Succinate, a cardioselective beta-blocker in sustained-release form. Together, they address both vascular resistance and heart rate regulation to offer comprehensive cardiovascular therapy.
Telmisartan (40 mg) works by selectively blocking angiotensin II receptors, preventing vasoconstriction and reducing aldosterone-mediated sodium and water retention. This action relaxes blood vessels and lowers blood pressure, improving overall vascular function and reducing strain on the heart. It is especially effective in protecting kidney function in hypertensive patients with diabetes or chronic kidney disease.
Metoprolol Succinate (25 mg SR) is a long-acting beta-1 adrenergic receptor blocker that slows the heart rate, reduces myocardial oxygen demand, and lowers blood pressure by diminishing the effects of adrenaline. Its sustained-release formulation ensures a consistent therapeutic effect over 24 hours with reduced risk of side effects such as sudden drops in blood pressure or bradycardia.
The combination of Telmisartan and Metoprolol offers superior blood pressure control compared to monotherapy and is beneficial for patients who require dual-action treatment. It is also ideal for hypertensive patients with a history of cardiovascular events, including angina, myocardial infarction, or arrhythmias.
Telbolife Beta 25 Tablet improves treatment adherence with once-daily dosing and helps in maintaining 24-hour blood pressure control, thereby reducing the risk of complications like stroke, heart failure, and kidney dysfunction.
Patients are advised to follow lifestyle changes alongside medication, including a low-sodium diet, regular exercise, stress management, and limiting alcohol intake. Regular monitoring of blood pressure and heart rate is recommended during therapy.